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There is increasing use of the vitreous cavity as a reservoir for drug delivery. We study the intraocular migration and distribution
of triamcinolone acetonide (TA) after injection into silicone oil tamponade agent during and after vitrectomy surgery ex vivo (pig
eye) and in vitro (glass bottle). For ex vivo assessment, intraocular migration of TA was imaged using real-time FLASHMRI scans
and high-resolution T2W imaging and the in vitromodel was monitored continuously with a video camera. Results of the ex vivo
experiment showed that the TA droplet sank to the interface of silicone oil and aqueous almost immediately after injection and
remained inside the silicone oil bubble for as long as 16 minutes. The in vitro results showed that, after the shrinkage of the droplet,
TA gradually precipitated leaving only a lumpofwhitish crystalline residue inside the droplet for about 100minutes. TA then quickly
broke the interface and dispersed into the underlying aqueous within 15 seconds, whichmay result in amomentary increase of local
TA concentration in the aqueous portion and potentially toxic to the retina. Our study suggests that silicone oil may not be a good
candidate as a drug reservoir for drugs like TA.
1. Introduction
The vitreous cavity has increasingly been used as a reser-
voir for drugs in conjunction with pars plana vitrectomy
to treat intraocular diseases [1]. For example, intravitreal
administration of corticosteroids (e.g., triamcinolone ace-
tonide, TA) becomes more and more popular to inhibit
choroidal neovascularization [2] or to decrease inflammation
[1, 3, 4]. However, effective postvitrectomy drug treatments
depend on the intraocular distribution of the drugs. Indeed,
a previous study [5] showed that vitrectomy surgery with
tamponade agent had a significant effect on intraocular drug
distribution.
In clinical practice, intraocular injection of TA at dif-
ferent concentrations was adopted locally to suppress cell
proliferation [6–9]. It was shown that TA concentration could
stay at a certain level for a long period (up to 3 months)
after injection [6]. However, risk factors such as intraocular
pressure elevation or RPE cell damage were reported after
injection of TA at high dosage [10]. For eyes undergoing
vitrectomy with silicone oil as tamponade agent, the portion
of aqueous in the vitreous chamber was much less than
normal eyes. This would cause an even higher postoperative
intraocular TA concentration after injection of TA at the same
dosage. As a result, it would be crucial to understand the
distribution of the TA after intravitreal injection, whether
it is released in a transient or slow manner. Currently, the
distribution of TA after vitrectomy surgery is inconclusive
among studies. In a preclinical study by Fernandes-Cunha et
al. using rabbit model, the majority of the TA injected after
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vitrectomy was measurable in the silicone oil and aqueous
humour up to 4 weeks after intravitreal injection [11]. A
clinical case report by Jonas showed a large variation of theTA
concentration in silicone oil among patients after injection
after vitrectomy surgery [12]. In a study using an artificial
vitreous space chamber [13], when TA suspension at high
concentration (200mg/mL) was injected into the silicone oil-
filled chamber, the suspension sank to the bottom of the
silicone oil within the first 5 minutes and started to sediment
from then on with no retrievable TA from the silicone oil
at the end. However, to the best of our knowledge, there is
currently no study investigating the distribution of the TA
immediately after injection using animal eye models.
This study aims to investigate the intraocular migra-
tion and distribution of TA after injection into silicone
oil tamponade agent (Siluron 2000) immediately following
vitreoretinal surgery. We used an ex vivo pig eye model
in combination with MRI techniques to allow visualization
and quantification of the TA droplet kinetics in an in-house
assembled drug distribution kit. For assessment over a longer
period of time, an in vitro glass bottlemodel was used instead,
and the migration and distribution of TA were monitored
with a video camera. We developed a novel method to inves-
tigate the drug kinetics immediately after administration.
Based on the findings of this study, we proposed potential
improvement or alternatives over current postvitrectomy
drug delivery procedure, to avoid the potential toxic effects
towards the pathology such as the detached retina.
2. Materials and Methods
Among various species, the anatomyof porcine eye, including
pupil, lens, macula-like structure, and retina vasculature
(which is fully vascularized, while other animals like rabbit
are not), is the second closest in similarity to human eyes
(right after the primates) [14–16]. As a result, pig model was
used for performing the vitrectomy surgery and assessing the
drug delivery.
Siluron 2000 was adopted as the intraocular tamponade
in vitrectomy surgery. It is a kind of conventional silicone
oils comprising pure polydimethylsiloxane. All chemicals
were purchased from Sigma-Aldrich (US) unless otherwise
mentioned.
2.1. Vitrectomy Surgery Procedure. Three freshly harvested
pig eyes were obtained from the Sheung Shui slaughterhouse
and kept in balanced salt solution (BSS) before surgery at 4∘C.
Within 3 hours after harvest, pig eyes underwent 3-port pars
plana vitrectomy (PPV).The 3-port PPVwas performed with
an operating microscope (Leica Microsystems AG, Switzer-
land) and vitrectomy machine (Storz Instrument Company,
US). Three small incisions with a diameter less than 2mm
were made 3mm posterior to the corneoscleral limbus with a
20-gaugeMVR blade for the insertion of an infusion cannula,
a pneumatic cutting device, and a light pipe. The cutter and
light pipe were positioned with a degree not smaller than
60∘ to avoid lens injury. Under constant infusion of BSS,
as much vitreous as possible was removed while avoiding
lens damage (Figure 1(a)). After the fluid-air exchange, the
vitreous cavity was filled with Siluron 2000 (Figure 1(b)).
After the operation, the sclerotomies were closed with 7-0
coated Vicryl sutures (ETHICON, Johnson & Johnson, US).
The bottom two incisions were closed first. For the incision
at the top, the infusion cannula was replaced with a 20-gauge
angiocath, with its plastic tip cut at 9mm such that the tip can
enter the silicone oil bubble (Figure 1(c)).The back end of the
angiocath was later connected to an extended cannula.
2.2. Drug Distribution Kit Assembly. After vitrectomy
surgery, the pig eyes were placed and fixed in a self-
assembled MRI compatible drug distribution kit (Figure 2),
which were used to facilitate the dynamic T1-weighted MRI
scan during the drug injecting. Agarose gel (2%) was poured
into a 50mL conical tube to fix the pig eye position and to
avoid random movement. The position of the pig eyes was
adjusted to ensure the highest magnetic resonance signal
inside the MRI machine. A 1m long plastic tube filled with
the TA suspension was connected to the angiocath. Air
bubbles were carefully eliminated to avoid any potential
artefact during the subsequent MRI acquisitions. The eyeball
was then placed in the 50mL conical tubes containing
solidified agarose and stationed in the upright position.
Additional melted agarose gel was then poured into the
tube until the entire eyeball was covered. A hole of 2 cm
diameter was drilled at the centre of the cap in order to let
the extended plastic tube come through (Figure 2(c)). The
tube was then connected to a 1mL syringe. The assembled
drug distribution kit was then inserted into the phantom
holder of the MRI machine.
2.3. Magnetic Resonance Imaging. MRI scan was performed
within one hour after the vitrectomy surgery using a 7-
TeslaMR system (70/16 PharmaScan, Bruker BioSpinGmbH,
Germany) and a volume transmit-receive head coil.The drug
injection and distribution processes were recorded in real
time with T1-weighted MRI for 6 minutes. Meanwhile, high-
resolution T2-weighted MRI was also taken at time points
immediately before drug injection and 5 minutes after the
completion of T1-weighted MRI scan, for the purpose of
comparing the intraocular environment before and after drug
injection.
The scanning parameters of the T1-weighted and T2-
weighted MRI are summarised in Table 1.
After putting the drug distribution kit into the MRI
machine, the first T2-weightedMRI scan was performed.The
T1-weighted MRI scan started immediately after that. The
coronal scanning orientation was selected as it can reveal the
drug droplet sinking procedure clearly. The coronal axle of
both the T2-weighted MRI scan and T1-weighted MRI scan
was adjusted to the upright position in order to keep the
measurements of the sinking speed accurate and comparable
to each other. 0.1mL TA suspension was injected into the
silicone oil bubble within 10 seconds. Subsequently, the T1-
weighted MRI continued to record the sinking and sedimen-
tation processes of the drug droplet for up to 6 minutes. Five
minutes after the completion of the T1-weighted MRI scan,
another T2-weighted MRI scan was performed.
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Figure 1: Steps of vitrectomy surgery on pig eye. (a) The vitreous was removed using a pneumatic cutting device and a light pipe (Total Plus
Pak with Accurus, Alcon, US) with the help of contact lens (Ocular Instruments, US). (b) Siluron 2000 was injected after vitreous removal
and air-fluid exchange. (c) Schematic diagram of the vitrectomized pig eye with an angiocath inserted into the silicone oil bubble.
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Figure 2: Assembly of the drug distribution kit. Step 1: 22.5mL
agarose gel was poured into the 50mL tube. Step 2: the pig eye was
placed on top of the solidified agarose gel at the upright positionwith
the angiocath connected to the extended plastic tube. Step 3: more
agarose gel was poured to cover and fix the pig eye inside the 50mL
tube.
To quantify the intraocular kinetics of the TA droplet
inside the silicone oil bubble, we measured the distance
between the TA droplet and the bottom of the silicone oil
bubble along time afterTA injection. Each distancewas calcu-
lated as the average of three measure separate measurements.
The sinking speed of the drug droplet was then measured
from the acquired image series by calculating its position
difference from images acquired at different time points.
2.4. In Vitro Investigation of Drug Distribution. In order to
further study the distribution of the TA droplet in silicone
oil for an extended period of time, in vitro studies were
performed in 20mL glass bottles (2.5 cm in diameter) as
a pseudo eye model. We hypothesized that TA suspension
with higher concentration could break the surface tension
between silicone oil and aqueous more easily and so would
stay inside the silicone oil bubble for a shorter time. Tomimic
the intraocular aqueous environment during vitrectomy, the
bottle was filled with 10mL BSS first. 10mL Siluron 2000
was then filled and formed a silicone oil layer above the
BSS layer. 0.1mL TA suspension with different concentration
(2mg/mL, 10mg/mL, or 40mg/mL) was injected at the top
of silicone oil layer. A video camera was used to monitor the
process continuously and take pictures automatically at a time
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Table 1: The scanning parameters of both the T1-weighted MRI and the T2-weighted MRI.
T1-weighted MRI T2-weighted MRI
Imaging sequence FLASH RARE
Repetition time (TR) 52ms 4200ms
Echo time (TE) 3ms 65ms
Slice thickness 1mm 1mm
Slice gap 0.1mm 0.1mm
Acquisition matrix 128 × 128 256 × 256
In-plane resolution 258 𝜇m × 258 𝜇m 129 𝜇m × 129𝜇m
Field of view 3.3mm × 3.3mm 3.3mm × 3.3mm
Number of slices 5 20
RARE factor N/A 8
Average number 1 2
Total scanning duration 6min (5 s per time point for 72 time points) 5min each before and after T1-weighted MRI
interval of 15 seconds.The sedimentation time was computed
starting from the time when the drug bubble reached the
interface of silicone oil and BSS and ending when it broke the
surface tension and dispersed into the underlying BSS layer.
The experiment was repeated 7 times and averaged. One-way
ANOVA followed by Bonferroni posttest was performed to
evaluate the statistical significance of the differences among
different groups (Prism version 5.0, GraphPad Software, Inc.,
San Diego, CA). Bonferroni posttest was performed only
when the means of the groups were significantly different
(𝑃 < 0.05).
3. Results
3.1. Ex Vivo Investigation of Postinjection Drug Distribution.
From the T1-weighted MRI images in the ex vivo study, it
was observed that the TA droplet did not come out of the
needle until 10 to 20 seconds after the injection started. Then
it entered the silicone oil bubble within 1 second. Presumably,
this was due to the viscosity of the silicone oil inside the
headmost of the needles that blocked the drugs from exiting
the needlepoint. Subsequently, the TA suspension showed
rapid gravitation and sedimentation to the lower part of the
silicone oil bubble. Figure 3 showed the image series from
the time when 0.1mL TA droplet was fully injected into the
silicone oil bubble until it sank onto the interface of the
silicone oil bubble and the underlying aqueous layer. The
number under each image was its frame number during real-
time recording. According to theT1-weightedMRI parameter
setup, the time interval between adjacent frames was 5
seconds. Figure 3(a) showed a representative image frame
whichwas taken at the 150th second after the commencement
of T1-weighted MRI. Based on the calculation from the
image frames, the average sinking speed was 0.044mm/s.
The diameter of the pig eye vitreous chamber (which was
measured by the distance from top to bottom in the coronal
sections images) was about 3 cm. From the MRI images, the
height of the silicone oil bubble was between 1 cm and 2 cm.
As a result, it could be concluded that it took about 6 minutes
for the drug droplet to sink onto the interface of silicone oil
and intraocular aqueous before sedimentation.
The preinjection and postinjection high-resolution T2-
weighted images were taken immediately before drug injec-
tion and 5 minutes after the completion of T1-weighted MRI
scan (Figure 4). MRI images showed clearly that the injected
TA drug droplet remained intact as a spherical droplet inside
the silicone oil bubble at 16 minutes after injection (Figure 4),
suggesting that TA droplets could stay inside the silicone oil
bubble till the end of the experimental period in the ex vivo
setup.
The postinjection TA kinetics was measured in three
independent experiments (Figure 5). The initial distance
depends on the insertion position of the angiocath tip. The
TA droplet sank in a linear fashion at a relatively constant
speed before touching the silicone oil aqueous interface
(3.23mm/min, 3.03mm/min, and 3.44mm/min for each
injection). The TA droplet sank to the bottom of the silicone
oil bubble in 5 minutes after injection in all experiments.
During the postvitrectomy drug delivery, the exact insertion
site for the TA injection may vary from case to case. This is
reflected in our result. The insertion site of the angiocath tip
varies among the 3 experiments. For the 1st experiment, the
injection site is lower than the other two, and the TA droplet
sinks to the bottom of the silicone oil bubble earlier (about
3 minutes after injection, as shown in red dots in Figure 5).
For the 3rd experiment, the TA droplet sank at a lower speed
initially compared to the other 2 experiments (as shown in
green dots in Figure 5). This is due to the fact that the initial
injection site of the TA droplet is relatively closer to the lens.
TheTAdroplet has to slide down along the lens before sinking
in full speed.
3.2. In Vitro Investigation of Drug Distribution. The position
and status of the TA droplet were further investigated using a
20mL glass bottle in the in vitro study. Images were recorded
every 15 seconds after TA injection into the silicone oil layer.
The result showed that the TA droplet generally remained
intact inside the silicone oil layer. TA gradually precipitated
leaving only a lump of whitish crystalline sediment inside
the droplet until about 100 minutes later when it quickly
broke the silicone oil aqueous interface and dispersed into
the underlying aqueous within a very short time (less than
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Figure 3: Representative image series of dynamic T1-weighted MRI. (a)The angiocath tip, the drug droplet, and the pig eye lens were clearly
shown in this image frame taken withMRI. (b) MR Image series showed the intraocular kinetics of a TA droplet inside the silicone oil bubble
within 6 minutes after the injection.The index number under each image represents its corresponding time point after the image acquisition
starts. There are in total 72 time points within each scanning session. At each time point, the T1-weighted MRI is acquired in 5 seconds.
TA droplet
Lens
Siluron 2000
PostinjectionPreinjection
Figure 4: Representative T2-weighted images of vitrectomized pig eyes before and after drug injection. High-resolution T2-weighted images
were taken immediately before drug injection (before injection) and 5 minutes after the completion of dynamic T1-weighted MRI scan (after
injection). The scanning parameter was adjusted in order to reduce the chemical shift artifact (CSA) while maintaining the signal to noise
ratio (SNR) level. The TA drug droplet was well represented in the postinjection images, which indicated that the drug droplets could sink
and stay inside Siluron 2000 silicone oil bubble for up to 16 minutes after the injection. The trail of TA suspension in the postinjection image
indicated the small position change of the droplet during the 5 minutes scanning time for the T2-weighted image.
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Figure 5: Distance from the TA droplet to the bottom of silicone oil
bubble after injection. The dots in the graph represent the distance
between the bottom of the TA droplet and the bottom of the silicone
oil bubble along the time after injections. The 3 different colours
represent 3 independent experiments performed on 3 different pig
eyes. 0.1mL TA suspension was injected into the pig eyes in each
experiment. Similar to the real case scenario during postvitrectomy
drug injection, the insertion sites of the angiocath tip vary among 3
experiments, resulting in slightly different kinetics of the TAdroplet.
The insertion site for the 1st experiment is lower than the other
two, resulting in a shorter sinking time. The insertion site of the 3rd
experiment is closer to the lens, resulting in a slow initial dropping
speed as the TA droplet slides down along the lens before sinking
straight.
15 seconds of the recording interval) (Figure 6). TA droplets
of different concentration were used in this study and they
displayed similar behaviour. The sedimentation time of TA
droplet at 2, 10, and 40mg/mL was computed and there
was no significant difference among them (Figure 7). This
suggested that the sedimentation time was not related to the
concentration of TA in the droplet. However, the standard
deviation of the sedimentation time for TA suspension at
40mg/mL was very large, suggesting that the TA droplet at
high concentration may have a more unpredictable sedimen-
tation time.
4. Discussion
Ophthalmic drug release and distribution have receivedmore
and more attention in recent years [17]. Different materials
and methods have been studied for drug sustainability and
slow release systems [18]. For instance, some studies used
collagen gel [19], while others used implant of drug sur-
rogate [20]. Meanwhile, different vitreous substitutes have
been developed and studied [21, 22], and silicone oil is the
most widely used vitreous substitute currently. Clinically, TA
suspension is injected after vitrectomy surgery. Therefore, it
is the aim of this study to investigate the feasibility of silicone
oil as a drug reservoir by evaluating the sustainability of drugs
being injected.
MRI allows noninvasive and nondestructive assessments
of the eye over time without depth limitation [23, 24]. The
dynamic T1-weighted MRI technique is a useful tool to assist
monitoring the migration and distribution of drug droplet
after intraocular injection in the ex vivo pig eye model.
Here, we showed clearly the kinetics of the drug droplet
inside the silicone oil bubble, which sank to the inferior
part of the silicone oil bubble. In addition, the T2-weighted
MRI acquired at a later time point showed that the TA
droplet stayed intact without breaking and did not mix with
either silicone oil or intraocular liquid for up to 16 minutes,
suggesting that the drug stayed inside the droplet without
being dispersed into the silicone oil bubble.This was different
from a previous study [13] where the injected TA droplet
sank through the silicone oil bubble and lost its spherical
shape at only 5minutes after injection in an artificial chamber
and finally sedimented below the silicone oil bubble. This
difference was probably caused by the different concentration
of TA between their study (200mg/mL) and this study
(40mg/mL). Indeed, TA droplet at lower concentrations (no
higher than 10mg/mL) remained stable inside the silicone
oil bubble for several hours in our in vitro study. However,
the TA droplet status became unpredictable inside silicon oil
at higher concentration. Moreover, although the T1-weighted
MRI images together with the T2-weighted MRI showed an
intact TA droplet inside the silicone oil bubble for at least
16 minutes, it was difficult to distinguish whether TA inside
the drug droplet remained as a suspension or it precipitated
out to become crystalline sediment. But both our in vitro
study (Figure 6) and Spitzer et al.’s study [13] showed that
about 90 minutes after injection only a lump of whitish TA
crystalline sediment remained in the droplet. Therefore, the
sustainability of TA inside the silicone oil was in question. In
addition, TA sediments finally broke the silicone oil aqueous
surface tension and dispersed into the underlying aqueous
within a very short time, which would result in a momentary
increase of local TA concentration in the aqueous portion. As
it was reported that high concentration of TA had toxic effect
to the retina [10], this observation suggested that silicone oil
may not be a good candidate as a drug reservoir for TA.
It was interesting to observe that the TA droplet did
not break the interface between silicone oil bubble and the
liquid around it until almost 100 minutes later. One factor
that stopped the TA droplet from breaking might be its
low specific gravity. It has been shown that TA precipitation
started at 5 minutes after injection [13]. Also, after comparing
the sedimentation time of TA at different concentrations, we
hypothesized that the reason which caused the TA droplet
to finally break the oil-aqueous surface tension was the
larger specific gravity and irregular shape of the crystallized
TA precipitate. Whether this specific gravity difference can
contribute to the silicone oil aqueous interface break needed
to be further investigated. In addition, the irregular shape of
TA crystalsmight also contribute to the surface tension break,
especially for the case of unpredictable sedimentation time
for TA droplet at high concentration (40mg/mL).
The interfacial phenomena, especially the interfacial ten-
sion between vitreous substitution and aqueous, are impor-
tant factors for intravitreal drug delivery.Themolecules at the
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Figure 6: Continuous monitoring of the TA drug droplet in the 20 mL glass bottle model. This timer recorded the time elapsed after the TA
droplet injection. (a) The droplet finished sinking inside the silicone oil and began to sediment. (b) The TA sediment gradually precipitated
to the bottom of the drug droplet before finally breaking the surface tension of silicone oil and BSS. (c) The TA dispersed into the BSS layer
after breaking the surface tension.
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Figure 7: Sedimentation time of 0.1mL TA droplet at different con-
centration. One-way ANOVA followed by Bonferroni posttest was
performed to evaluate the statistical significance of the differences
among different groups. Error bars represent standard deviation.
No significant difference was found among these three groups.
The variation of data from the TA droplet with a concentration of
40mg/mL indicated the unpredictability of its sedimentation time.
liquid surface possess more free energy than the molecules
inside its bulk material. Therefore, both the silicone oil
bubble and the TA droplet tend to reduce its surface at the
interface to minimise the total energies within, resulting in
a smooth interface [25]. Extra energy is needed in order to
break the interface between the silicone oil and the aqueous.
The energy required to increase each unit area surface is
defined as the surface tension, or interfacial tension. The
surface tension at the silicone oil aqueous interface is around
30mN/m (milliNewton per meter) at room temperature [21].
The presence of solute also affects the surface tension. The
solubility of TA in distilled water is very low (21mg/L at room
temperature) [26], and TA is insoluble in silicone oil [27].
This insolubility characteristic leads to the crystallized TA
to sediment onto the interface between the two liquids, dis-
rupting its smoothness and effectively increasing the surface
area. Such increased surface area can also be considered as a
result of the excessive energy, which comes from the gravity
applied onto the crystallized TA. The tendency to release
such extra energy may contribute to the final breakdown of
the silicone oil aqueous interface. Methods such as dynamic
surface tension measurement can be used to further analyse
the liquid-liquid interfacial tension in detail [25].
Previous studies [13] showed that TA could not be
retrieved within the silicone oil after intravitreal injection
using an artificial vitreous chamber. It was therefore sug-
gested that premixing the TA suspension with the silicone oil
before vitrectomy would be beneficial. It would be interesting
to test this method using our pig eye model. However, the
TA/silicone oil suspension should be thoroughly mixed as
TA and silicone oil would segregate slowly into two phases.
In addition, the amount of TA to be mixed with silicone oil
should be calculated in caution to avoid toxicity effect due to
drug overdose. Dynamic T1-weighted MRI could be used to
determine if the segregation of TA from silicone oil would still
occur.
Various ocular implants have been proposed in the field
of ocular drug delivery as the alternative possible vitreous
substitutions to provide localised controlled drug release
[28–30]. Those implants could potentially be considered
as alternative drug reservoirs for TA administration after
vitrectomy surgery. Some of such implants are nonbiodegrad-
able and provide very slow and long drug kinetics, such as
polyvinyl alcohol (PVA), ethylene vinyl acetate (EVA), and
polysulfone capillary fibre (PF) [28]. Recently, biodegradable
implants have attracted a lot of attention for sustained
drug release, with the advantage of eliminating the need
for surgical removal procedure. Examples of such implant
include polylactic acid (PLA), polyglycolic acid (PGA), and
polylactic-co-glycolic acid (PLGA) [31].
Indeed, the drug distribution characteristic in the normal
eye would be worth studying in order to compare with the
drug distribution in vitrectomized eyes. The ex vivo pig eye
model and in vitro glass bottle model had uncontrolled IOP
comparing to normal eyes.There is little research on the effect
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of different IOPs towards intraocular drug distribution. As
a result, further investigation could be conducted to study
whether IOP is a factor to influence the intraocular drug
distribution inside silicone oil-filled eyes.
5. Conclusion
In this paper, we present a novel method to investigate the
drug kinetics immediately after administration into vitrec-
tomized eyes.We presented a self-assembledMRI compatible
drug distribution kit using ex vivo pig eye model to monitor
the sinkage of TA droplet within the bubble of silicone
oil tamponade agent in real time using MRI. Furthermore,
with the use of an in vitro pseudo eye model in a 20mL
glass bottle, we managed to monitor the postinjection drug
kinetics for longer period of time and observed that the TA
gradually precipitated inside the droplet and finally broke the
silicone oil aqueous interface within short period of time and
dispersed into the underlying fluid. The result of this study
suggests that silicone oil may not be a good candidate as a
drug reservoir for drugs like TA. The unpredictable sudden
breakdown of liquid-liquid interface might induce transient
concentration increase causing a potential postinjection toxic
side effect. As a result, during the treatment of intraocular dis-
eases such as retinal detachment with pars plana vitrectomy
surgery, caution should be taken when injecting drugs (e.g.,
corticosteroids) into the silicone oil tamponade agent. The
better alternative materials that can be both the tamponade
agent and the reservoir for sustained slow drug release still
remain to be investigated.
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